JP2016502984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502984A5 JP2016502984A5 JP2015546927A JP2015546927A JP2016502984A5 JP 2016502984 A5 JP2016502984 A5 JP 2016502984A5 JP 2015546927 A JP2015546927 A JP 2015546927A JP 2015546927 A JP2015546927 A JP 2015546927A JP 2016502984 A5 JP2016502984 A5 JP 2016502984A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cyclodextrin
- composition
- group
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 229920000858 Cyclodextrin Polymers 0.000 claims 7
- 125000004964 sulfoalkyl group Chemical group 0.000 claims 6
- 102000014150 Interferons Human genes 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 125000001033 ether group Chemical group 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 claims 3
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 3
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 claims 3
- 235000007242 delphinidin Nutrition 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 108700012411 TNFSF10 Proteins 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- -1 sulfoalkyl ether Chemical compound 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012222777.6 | 2012-12-11 | ||
| DE102012222777 | 2012-12-11 | ||
| EP13150909 | 2013-01-11 | ||
| EP13150909.3 | 2013-01-11 | ||
| PCT/EP2013/074957 WO2014090583A1 (de) | 2012-12-11 | 2013-11-28 | Delphinidin zur bekämpfung von melanomzellen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502984A JP2016502984A (ja) | 2016-02-01 |
| JP2016502984A5 true JP2016502984A5 (enExample) | 2016-11-10 |
| JP6234475B2 JP6234475B2 (ja) | 2017-11-22 |
Family
ID=49679524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546927A Expired - Fee Related JP6234475B2 (ja) | 2012-12-11 | 2013-11-28 | メラノーマ細胞に対抗するためのデルフィニジン |
| JP2015546930A Expired - Fee Related JP6234476B2 (ja) | 2012-12-11 | 2013-11-28 | メラノーマ細胞に対抗するためのデルフィニジン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546930A Expired - Fee Related JP6234476B2 (ja) | 2012-12-11 | 2013-11-28 | メラノーマ細胞に対抗するためのデルフィニジン |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9511047B2 (enExample) |
| EP (2) | EP2931286B1 (enExample) |
| JP (2) | JP6234475B2 (enExample) |
| KR (2) | KR102164174B1 (enExample) |
| CN (2) | CN104918622A (enExample) |
| CA (2) | CA2893883A1 (enExample) |
| HK (1) | HK1215392A1 (enExample) |
| WO (2) | WO2014090583A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014075935A1 (de) | 2012-11-15 | 2014-05-22 | Sapiotec Gmbh | Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff |
| KR102164174B1 (ko) * | 2012-12-11 | 2020-10-12 | 자피오텍 게엠베하 | 흑색종 세포를 퇴치하기 위한 델피니딘 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5946228A (ja) | 1982-09-08 | 1984-03-15 | Zeria Shinyaku Kogyo Kk | 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法 |
| HU199444B (en) | 1985-09-10 | 1990-02-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom |
| GB8907008D0 (en) | 1989-03-28 | 1989-05-10 | Inverni Della Beffa Spa | Intermediates useful for the synthesis for delphinidin chloride |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| ZA962214B (en) | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
| EP1666591B1 (en) * | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| GB2307176A (en) | 1995-11-15 | 1997-05-21 | Todd Selwyn Everest | Anti-inflammatory clathrating agents for topical use |
| HUP9701945A3 (en) | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
| JP4101346B2 (ja) | 1998-02-18 | 2008-06-18 | ダイセル化学工業株式会社 | 酸化触媒系及びそれを用いた酸化方法 |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| CA2320772A1 (en) | 1998-02-23 | 1999-08-26 | Cyclops, Ehf. | High-energy cyclodextrin complexes |
| GB2350297A (en) | 1999-05-27 | 2000-11-29 | Abbott Lab | Injectable halogenated anesthetic formulation in emulsion form |
| US6576261B1 (en) | 1999-08-11 | 2003-06-10 | Josef Pitha | Potentiation of inclusion complex formation of cyclodextrin derivatives |
| WO2001030391A2 (en) | 1999-10-27 | 2001-05-03 | Farmarc Nederland Bv | Pharmaceutical composition containing midazolam |
| DE60114860T2 (de) | 2000-09-12 | 2006-05-24 | Meiji Seika Kaisha Ltd. | Verfahren zur Herstellung von gereinigtem Anthocyanin und kristallinem Anthocyanin |
| EP1383445A4 (en) | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP2003171274A (ja) | 2001-12-07 | 2003-06-17 | Tomihiko Higuchi | 薬剤耐性菌感染症治療のための医薬組成物および消毒剤 |
| WO2003063824A2 (en) | 2002-02-01 | 2003-08-07 | Shimoda Biotech (Pty) Ltd | Pharmaceutical composition |
| JP2004238336A (ja) * | 2003-02-07 | 2004-08-26 | Sanei Gen Ffi Inc | 水易溶性包接フラボノイド類の製造方法 |
| US20050013880A1 (en) * | 2003-03-06 | 2005-01-20 | Magnuson Bernadene Ann | Anthocyanin-rich compositions and methods for inhibiting cancer cell growth |
| CA2520522C (en) | 2003-03-28 | 2012-05-29 | Ivax Corporation | Cladribine formulations for improved oral and transmucosal delivery |
| JPWO2005067905A1 (ja) | 2004-01-14 | 2007-12-27 | 株式会社大塚製薬工場 | プロポフォール含有脂肪乳剤 |
| CN1317961C (zh) | 2004-03-25 | 2007-05-30 | 吴朝琴 | 冻干草莓加工工艺 |
| CN100342026C (zh) * | 2004-05-13 | 2007-10-10 | 深圳新鹏生物工程有限公司 | 重组人可溶性肿瘤坏死因子相关凋亡诱导配体制备方法 |
| WO2006076387A2 (en) * | 2005-01-11 | 2006-07-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Cyanidin-3-glucoside as an anti-neoplastic agent |
| DE102005017775A1 (de) | 2005-04-13 | 2006-10-19 | Schering Ag | Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins |
| KR100733913B1 (ko) * | 2005-08-30 | 2007-07-02 | 한국화학연구원 | 안토시아닌을 포함하는 뇌세포 보호제와 뇌경색 및 뇌졸중예방 또는 치료제 |
| US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| US9000048B2 (en) | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| KR100756656B1 (ko) | 2006-12-12 | 2007-09-10 | 한국화학연구원 | 안토시아닌을 포함하는 뇌경색 또는 뇌졸중 예방 및 개선용건강식품 |
| KR100880876B1 (ko) | 2007-04-11 | 2009-01-30 | 경상대학교산학협력단 | 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 피판이나조직의 허혈-재관류 손상의 예방 또는 치료용 의약 조성물 |
| WO2009018326A2 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Soluble pyrone analogs methods and compositions |
| JP5574600B2 (ja) | 2007-12-17 | 2014-08-20 | 日本製薬工業株式会社 | 吸収性骨疾患の予防・治療剤 |
| EP2106786A1 (de) | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
| US7635773B2 (en) * | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US20120083460A1 (en) | 2009-03-25 | 2012-04-05 | San Ei Gen F.F.I., Inc. | Readily water-soluble isoquercitrin composition |
| EP2437770A4 (en) | 2009-06-05 | 2013-11-06 | Univ Colorado Regents | ANTIMICROBIAL PEPTIDES |
| KR101625882B1 (ko) | 2009-10-21 | 2016-05-31 | 마뀌 뉴 라이프 에스. 에이. | 안토시아니딘을 포함하는 조성물 및 이용방법 |
| EP2345427A1 (de) | 2010-01-14 | 2011-07-20 | SapioTec GmbH | Flurankomplex |
| CN106036793B (zh) | 2010-03-13 | 2020-11-06 | 伊斯顿庞德实验室有限公司 | 结合脂肪的组合物 |
| DE102010042615A1 (de) | 2010-10-19 | 2012-04-19 | Wacker Chemie Ag | 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel |
| AU2010366535A1 (en) | 2010-12-31 | 2013-07-11 | Eastpond Laboratories Limited | Cellular hydration compositions containing cyclodextrins |
| DK2484350T3 (en) | 2011-02-04 | 2016-08-01 | Norbert Univ -Prof Dr Med Roewer | A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt |
| JP6193970B2 (ja) | 2012-03-30 | 2017-09-06 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対するデルフィニジンの使用 |
| CA2869056C (en) | 2012-03-30 | 2020-02-25 | Sapiotec Gmbh | Anthocyanidin complex |
| JP2015534970A (ja) | 2012-10-17 | 2015-12-07 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ | 多発性骨髄腫の治療のためのアントシアニジン複合体 |
| WO2014075935A1 (de) | 2012-11-15 | 2014-05-22 | Sapiotec Gmbh | Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff |
| KR102164174B1 (ko) * | 2012-12-11 | 2020-10-12 | 자피오텍 게엠베하 | 흑색종 세포를 퇴치하기 위한 델피니딘 |
| EP2913050A1 (de) | 2014-02-28 | 2015-09-02 | SapioTec GmbH | Verfahren zur Herstellung eines Flurankomplexes |
| EP2913366A1 (de) | 2014-02-28 | 2015-09-02 | SapioTec GmbH | Anthocyanidin-Komplex |
-
2013
- 2013-11-28 KR KR1020157018731A patent/KR102164174B1/ko not_active Expired - Fee Related
- 2013-11-28 JP JP2015546927A patent/JP6234475B2/ja not_active Expired - Fee Related
- 2013-11-28 US US14/651,264 patent/US9511047B2/en not_active Expired - Fee Related
- 2013-11-28 CA CA2893883A patent/CA2893883A1/en not_active Abandoned
- 2013-11-28 WO PCT/EP2013/074957 patent/WO2014090583A1/de not_active Ceased
- 2013-11-28 HK HK16103394.8A patent/HK1215392A1/zh unknown
- 2013-11-28 EP EP13798323.5A patent/EP2931286B1/de not_active Not-in-force
- 2013-11-28 KR KR1020157018732A patent/KR20150107742A/ko not_active Withdrawn
- 2013-11-28 JP JP2015546930A patent/JP6234476B2/ja not_active Expired - Fee Related
- 2013-11-28 CN CN201380064588.0A patent/CN104918622A/zh active Pending
- 2013-11-28 CN CN201380064614.XA patent/CN104936601A/zh active Pending
- 2013-11-28 EP EP13815384.6A patent/EP2931287B1/de not_active Not-in-force
- 2013-11-28 US US14/651,262 patent/US9949947B2/en not_active Expired - Fee Related
- 2013-11-28 WO PCT/EP2013/074991 patent/WO2014090586A1/de not_active Ceased
- 2013-11-28 CA CA2893881A patent/CA2893881C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516808A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| MX2010002278A (es) | Farmacos antivirales para el tratamiento de una infeccion por arenavirus. | |
| JP2013509429A5 (enExample) | ||
| JP2016074736A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| JP2014530220A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| Tan et al. | Sustained release and cytotoxicity evaluation of carbon nanotube‐mediated drug delivery system for betulinic acid | |
| JP2014513089A5 (enExample) | ||
| JP2014167010A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| JP2010539082A5 (enExample) | ||
| JP2012046489A5 (enExample) | ||
| FI3792254T3 (fi) | Kiteisiä metyylitioniniumkloridihydraatteja | |
| JP2020097577A5 (enExample) | ||
| JP2015098469A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2014506233A5 (enExample) | ||
| JP2014509653A5 (enExample) | ||
| JP2017515840A5 (enExample) |